Blockade of EGFR improves responsiveness to PD-1 blockade in <i>EGFR</i> -mutated non–small cell lung cancer
Eri Sugiyama(Chiba Cancer Center), Hiroyoshi Nishikawa(Immunité et Cancer), Sayoko Shinya(Chiba Cancer Center), Keisuke Kataoka(Maryland Oncology Hematology), Yoshiko Takeuchi(Chiba Cancer Center), Yosuke Togashi(Okayama University), Kōichi Goto(National Cancer Center Hospital East), Masahiro Tsuboi(National Cancer Center Hospital East), Genichiro Ishii(National Cancer Center Hospital East), Yasushi Shintani(The University of Osaka), Kenta Tane(Thoracic Surgery Foundation), Yasuko Tada(Osaka University), Eiichi Sato(Kagoshima University), Meinoshin Okumura(The University of Osaka)
Cited by 285
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
|The Lancet|2022|1.6k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k